Oxford’s COVID-19 Vaccine Begins Testing in Human Volunteers
By HospiMedica International staff writers Posted on 25 Jun 2020 |
Image: Oxford`s COVID-19 Vaccine Begins Testing in Human Volunteers (Photo courtesy of University of Oxford)
The University of Oxford’s (Oxford, UK) candidate for a coronavirus vaccine has entered the human trial stage with researchers commencing testing of the COVID-19 vaccine in human volunteers.
The new vaccine called ChAdOx1 nCoV-19 is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein, and has been produced in Oxford. It is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it is impossible for it to grow in humans. Genetic material has been added to the ChAdOx1 construct, that is used to make proteins from the COVID-19 virus (SARS-CoV-2) called Spike glycoprotein (S). This protein is usually found on the surface of SARS-CoV-2 and plays an essential role in the infection pathway of the SARS-CoV-2 virus. The SARS-CoV-2 coronavirus uses its spike protein to bind to ACE2 receptors on human cells to gain entry to the cells and cause an infection. By vaccinating with ChAdOx1 nCoV-19, the researchers are hoping to make the body recognize and develop an immune response to the Spike protein that will help stop the SARS-CoV-2 virus from entering human cells and therefore, prevent infection.
In March, the researchers began screening healthy volunteers (aged 18-55) to test the ChAdOx1 nCoV-19 vaccine against COVID-19 in healthy volunteers. The study aims to assess whether healthy people can be protected from COVID-19 with the vaccine and also provide valuable information on safety aspects as well as its ability to generate good immune responses against the virus. The participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine or a licensed vaccine (MenACWY) that will be used as a ‘control’ for comparison. To assess whether the ChAdOx1 nCoV-19 vaccine works to protect from COVID-19, the researchers will compare the number of infections in the control group with the number of infections in the vaccinated group. If the levels of virus transmission in the community remain high, the researchers expect to get enough data in a couple of months to confirm that the vaccine works, although this could take up to six months if transmission levels drop.
Related Links:
University of Oxford
The new vaccine called ChAdOx1 nCoV-19 is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein, and has been produced in Oxford. It is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it is impossible for it to grow in humans. Genetic material has been added to the ChAdOx1 construct, that is used to make proteins from the COVID-19 virus (SARS-CoV-2) called Spike glycoprotein (S). This protein is usually found on the surface of SARS-CoV-2 and plays an essential role in the infection pathway of the SARS-CoV-2 virus. The SARS-CoV-2 coronavirus uses its spike protein to bind to ACE2 receptors on human cells to gain entry to the cells and cause an infection. By vaccinating with ChAdOx1 nCoV-19, the researchers are hoping to make the body recognize and develop an immune response to the Spike protein that will help stop the SARS-CoV-2 virus from entering human cells and therefore, prevent infection.
In March, the researchers began screening healthy volunteers (aged 18-55) to test the ChAdOx1 nCoV-19 vaccine against COVID-19 in healthy volunteers. The study aims to assess whether healthy people can be protected from COVID-19 with the vaccine and also provide valuable information on safety aspects as well as its ability to generate good immune responses against the virus. The participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine or a licensed vaccine (MenACWY) that will be used as a ‘control’ for comparison. To assess whether the ChAdOx1 nCoV-19 vaccine works to protect from COVID-19, the researchers will compare the number of infections in the control group with the number of infections in the vaccinated group. If the levels of virus transmission in the community remain high, the researchers expect to get enough data in a couple of months to confirm that the vaccine works, although this could take up to six months if transmission levels drop.
Related Links:
University of Oxford
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans